Targeted in vivo expression of IFN-γ-inducible protein 10 induces specific antitumor activity

Yang, Xiuli; Chu, Yiwei; Wang, Ying; Zhang, Ruihua; Xiong, Sidong

doi:10.1189/jlb.0306212

Cited by 61 publications

(47 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…the direct effects on cancer cells, it has also been reported that CXCL10 exerts antitumor activities by inducing immune-stimulating and angiostatic effects (27)(28)(29)(30). However, the role of endogenous CXCL10 in the development of primary cancers and their metastatic foci has not been addressed.…”

Section: Discussionmentioning

confidence: 99%

CXCL10 Promotes Osteolytic Bone Metastasis by Enhancing Cancer Outgrowth and Osteoclastogenesis

Lee

Kim²,

Kim³

et al. 2012

Cancer Research

View full text Add to dashboard Cite

Amplification of the chemokines CXCL10 and RANKL has been suggested to promote osteoclast differentiation and osteolytic bone metastasis, but a function for endogenous CXCL10 in these processes is not well established. In this study, we show that endogenous CXCL10 is critical to recruit cancer cells to bone, support osteoclast differentiation and promote for the formation of osteolytic bone metastases. Neutralizing CXCL10 antibody reduced migration of cancer cells expressing the CXCL10 receptor CXCR3, and loss of CXCR3 or CXCL10 decreased bone tumor burden in vivo. Bone colonization augmented host production of CXCL10, which was required for cancer growth and subsequent osteolysis. Direct interactions between cancer cells and macrophages further stimulated CXCL10 production from macrophages. Growth of bone metastases required CXCL10-stimulated adhesion of cancer cells to type I collagen as well as RANKL-mediated osteoclast formation. Together, our findings show that CXCL10 facilitates trafficking of CXCR3-expressing cancer cells to bone, which augments its own production and promotes osteoclastic differentiation. CXCL10 therefore may represent a therapeutic target for osteolytic bone metastasis. Cancer Res; 72(13); 3175-86. Ó2012 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

CXCL10 Promotes Osteolytic Bone Metastasis by Enhancing Cancer Outgrowth and Osteoclastogenesis

Lee

Kim²,

Kim³

et al. 2012

Cancer Research

View full text Add to dashboard Cite

show abstract

“…10,22,25,[51][52][53][54][55] The antitumor activity of IP-10 alone is usually moderate, but can in some cases be markedly increased by combined therapy, in particular with interleukin-2 and interleukin-12.…”

Section: Discussionmentioning

confidence: 99%

TNF-α and the IFN-γ-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma

et al. 2008

View full text Add to dashboard Cite

Interferon-g-inducible protein 10 is a potent chemoattractant for natural killer cells and activated T lymphocytes. It also displays angiostatic properties and some antitumor activity. Tumor necrosis factor-a (TNF-a) is a powerful immunomodulating cytokine with demonstrated tumoricidal activity in various tumor models and the ability to induce strong immune responses. This prompted us to evaluate the antitumor effects of recombinant parvoviruses designed to deliver IP-10 or TNF-a into a glioblastoma. When Gl261 murine glioma cells were infected in vitro with an IP-10-or TNF-a-transducing parvoviral vector and were subcutaneously implanted in mice, tumor growth was significantly delayed. Complete tumor regression was observed when the glioma cells were coinfected with both the vectors, demonstrating synergistic antitumor activity. In an established in vivo glioma model, however, repeated simultaneous peritumoral injection of the IP-10-and TNF-a-delivering parvoviruses failed to improve the therapeutic effect as compared with the use of a single cytokine-delivering vector. In this tumor model, cytokine-mediated immunostimulation, rather than inhibition of vascularization, is likely responsible for the therapeutic efficacy.

show abstract

“…In contrast to wound repair, where the balance of angiogenic and angiostatic factors is temporarily disrupted, a permanent angiogenic overbalance during tumor development provides the tumor with nutrients and oxygen allowing growth and metastasis [22,23]. In spite of the angiogenic overbalance, tumors are still able to produce angiostatic chemokines such as IP-10 that may counteract the angiogenic chemokines and attract antitumoral lymphocytes [7,[24][25][26]. In addition, the angiostatic chemokine PF-4var has previously been reported to be inducible in vitro in cultured human mesenchymal osteosarcoma cells, whereas PF-4 production was rather detected in leukocytes, predominantly in platelets [16].…”

Section: Discussionmentioning

confidence: 99%

Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer

Verbeke¹,

Hertogh²,

Li³

et al. 2010

Human Pathology

View full text Add to dashboard Cite

Targeted in vivo expression of IFN-γ-inducible protein 10 induces specific antitumor activity

Cited by 61 publications

References 31 publications

CXCL10 Promotes Osteolytic Bone Metastasis by Enhancing Cancer Outgrowth and Osteoclastogenesis

CXCL10 Promotes Osteolytic Bone Metastasis by Enhancing Cancer Outgrowth and Osteoclastogenesis

TNF-α and the IFN-γ-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma

Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer

Contact Info

Product

Resources

About